Imatinib has been approved for the treatment of patients with BCR-ABL positive chronic myeloid leukemia (CML) and patients with Kit (CD117)-positive gastrointestinal stromal tumors. This evidence concerns the gene KIT and chronic myelogenous leukemia, BCR-ABL1 positive.